By Allison Murphy I am proud to say that I joined the Medical Science Liaison Society in its inaugural year of 2012. After spending a decade as an MSL at Eli Lilly, I see multiple benefits of the society for those currently working in this critical role that unifies life sciences companies and the medical …
The MSL Society: Delivering Value to Medical Affairs Professionals Read More »
We were inspired by a recent PharmaLive story on Lilly’s new initiative highlighting the key work that medical professionals undertake at the company during all facets and phases of drug discovery and development. The story notes that over 500 physicians, 700 pharmacists, and 1400 medical research scientists work at Lilly, and the company is touting …
Lilly, Biopharmaceutical Companies Impact Patient Care with Medical Professionals Read More »
Health care systems across the globe rely on the advice and counsel of health care professionals (HCPs) when making decisions on new therapies to approve appropriate levels of reimbursement for various pharmaceutical products. These regulatory and reimbursement advisers have various backgrounds, including health outcomes and economics, clinical pharmacy and medicine. Within each medical discipline, certain …
Pharmaceutical manufacturers will face longer regulatory approval times and lower reimbursement rates in the years ahead according to new IMS data. A recent IMS release summarizes market forecasting data, including reduced drug spending by public payers and more extensive reviews of new therapies. To navigate effectively through these new challenges, pharmaceutical companies will need a …
